Order: 0571-88177686
Fax: 0571-88177681
Support: support@biolynx.cn

Rev.: 2026-7-22

LMO2
Recombinant Rabbit Monoclonal Antibody
Product Datasheet

Catalog# BX50380
Clone# BP6347

Predicted Molecular Wt: 18kDa
Species Cross-reactivity: Human
Applications: IHC-P

Purity: ProA affinity purified IgG
Form: Liquid
Swissprot ID: P25791

Background:

LIM domain only protein 2 (LMO2) is a transcriptional regulator, it acts with TAL1/SCL to regulate red blood cell development. LMO2 also acts with LDB1 to maintain erythroid precursors in an immature state.

LMO2 is strongly expressed in germinal center B cells of lymphoid organs, erythroid and myeloid precursors, megakaryocytes, and vascular endothelium.

LMO2 is a useful IHC marker in lymphoma diagnosis and subclassification: it identifies germinal center B-cell origin in DLBCL (predicting better prognosis), distinguishes T-LBL from thymoma (positive in ~70% vs. negative), and serves as a reliable endothelial marker; its negativity in mature T/NK-cell and plasma cell neoplasms further aids differential diagnosis.

Subcellular location:
Nucleus

Recommended Method:
Heat induced epitope retrieval with Tris-EDTA buffer (pH 9.0), primary antibody incubate at RT (18°C-25°C) for 30 minutes.

Immunogen:
The synthetic peptide corresponding to Human LMO2 aa 1-50.

Storage Buffer:
PBS 59%, Sodium azide 0.01%, Glycerol 40%, BSA 0.05%.

Storage Conditions:
-25°C to -18°C

Shipment Instructions:
Shipped on blue ice. Upon delivery store at -25°C to -18 °C. Avoid freeze / thaw cycles.

Recommended Dilution:
IHC-P: 1:100-1:200



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil labelling LMO2 with BP6347.

Background References:

1. Zanelli M, et al. Cancers (Basel). 13(12):3102, 2021 Jun 21.

2. Latchmansingh KA, et al. Mod Pathol. 35(9):1220-1226, 2022 Sep.

Product QC'd by:

For research use only. Not for use in diagnostic or therapeutic applications.